Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05473143
Other study ID # MP-02-2023-10829
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 3, 2023
Est. completion date January 1, 2025

Study information

Verified date May 2024
Source Centre hospitalier de l'Université de Montréal (CHUM)
Contact Marie-Line Caron, BSc
Phone 514-890-8000
Email marie-line.caron.chum@ssss.gouv.qc.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A pilot randomized clinical trial comparing a protocol-based fluid management strategy to usual care in critically ill patients receiving kidney replacement therapy. The fluid management protocol is intended to achieve neutral or negative daily fluid balance by both preventing and treating fluid accumulation.


Description:

Severe acute kidney injury (AKI) in the intensive care unit (ICU) is almost uniformly complicated by fluid accumulation, thus making fluid removal a central component of the renal replacement therapy (KRT) prescription. Whereas the achievement and maintenance of euvolemia are critical objectives in the care of critically ill patients with severe AKI, there remain important knowledge gaps in our ability to effectively and safely deliver ultrafiltration. Multisystemic congestion resulting from fluid accumulation is believed to mediate adverse outcomes in this population and the timely use of mechanical fluid removal may improve prognosis. However, fluid removal may be associated with hemodynamic instability during KRT which may precipitate complications. The optimal fluid management strategy is currently unknown. The study is a pilot randomized clinical trial comparing a protocol-based fluid management strategy with usual care in critically ill patients receiving KRT. The fluid management protocol is intended to achieve neutral or negative daily fluid balance by both preventing and treating fluid accumulation. The protocol was designed to provide a standardized framework to prescribe fluid removal while allowing the attending care team to modify treatment targets according to their clinical evaluation. The primary objective of this trial is to determine whether the intervention results in a difference in cumulative fluid balance from randomization to 5 days. Feasibility will be documented including the ability to enroll the target population, protocol adherence, and the capacity to achieve follow-up through 90 days. Secondary outcomes will also include short-term patient outcomes, safety outcomes, and health resource utilization related to KRT delivery.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date January 1, 2025
Est. primary completion date September 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years 2. Admitted to the ICU 3. AKI during current hospitalization defined by the Kidney Disease: Improving Global Outcomes (KDIGO) criteria(1) as any of the following: Increase in serum creatinine by 27 µmol/L or more within any 48-hour window, or an increase in serum creatinine to 1.5 times baseline or more within the last 7 days, or a urine output less than 0.5 mL/kg/h for 6 hours. 4. Planned initiation of KRT within the following 12 hours or the receipt of KRT for AKI for =48 hours Exclusion Criteria: 1. Lack of commitment to maintain kidney, pharmacologic or respiratory support at the time of screening, or probable transition to comfort care within 48 hours according to the treating physician 2. Probable discharge from the ICU within the next 48 hours according to treating physician 3. Severe burn injury (>10% of body surface area) 4. Severe abnormality in serum sodium (>155 or <120 mmol/L) 5. Important ongoing fluid losses are present and/or are expected to require continued maintenance IV fluids uring the next 48 hours 6. The clinical care team believes that the proposed intervention is inappropriate.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Protocol-based fluid management
Fluid removal will be prescribed using a standardized template updated at least once per working day, before noon of each day, by the attending care team. This protocolized prescription will contain three components. Fluid removal will be prescribed using a standardized template updated at least once per working day, before noon of each day, by the attending care team. This protocolized prescription will contain three components. The first component of this prescription will be to define the 24h-fluid balance target either aiming for a negative fluid balance of 2 to 3% body weight (1.4-2.1 liters in a 70 Kg participant) (Option 1) or by aiming to avoid fluid accumulation by targeting a neutral fluid balance within 0.5% of body weight variation (-350 to +350 mL in a 70 Kg participant) (Option 2). The second component is to pre-specify a prescription for fluid removal using KRT. The third component is to prompt a daily re-evaluation of fluid intake by the attending care team.
Usual care
The net fluid removal and the rate of net fluid removal will not be protocolized and will be prescribed and adjusted according to the attending care team without any specific guidance. The use of the documents provided for the intervention group will not be permitted in the control arm.

Locations

Country Name City State
Canada Centre Hospitalier de l'Université de Montréal Montréal Quebec

Sponsors (1)

Lead Sponsor Collaborator
Centre hospitalier de l'Université de Montréal (CHUM)

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cumulative fluid balance The difference between quantifiable fluid intake and output From randomization to the end of day 5
Secondary Feasibility: Ability to successfully enroll Target >30% of fully eligible patients During screening and enrolment
Secondary Feasibility: Protocol adherence defined as >80% of participants adhering to the allocated treatment for 5 days after enrolment From randomization to the end of day 5
Secondary Feasibility: Ability to achieve follow-up Ability to achieve > 95% follow-up regarding all clinical outcomes From randomization through day 90.
Secondary Clinical: Death Death from any cause From randomization through day 90.
Secondary Clinical: Vasoactive therapy-free days A vasoactive-free day will be defined as = 2 hours of receipt of any vasoactive therapy provided by continuous infusion within a 24 hour period. Vasoactive therapy include norepinephrine, vasopressin, phenylephrine, epinephrine, dopamine >5mcg/kg/min, and angiotensin II. From randomization through day 28.
Secondary Clinical: Mechanical ventilation-free days A ventilator-free day will be defined as the receipt of = 2 hours of mechanical ventilation within a 24-hour period. From randomization through day 28.
Secondary Clinical: KRT-free days An KRT-free day will be defined receiving any KRT modality for = 2 hours within a 24 hours period. From randomization through day 28.
Secondary Clinical: ICU-free days An ICU-free day will be defined as admission to an ICU for = 2 hours within a 24 hours period. From randomization through day 90
Secondary Clinical: Hospital-free days Hospital-free days will be defined as a 24-hour period completely free of an inpatient hospitalization. From randomization through day 90
Secondary Dependence on KRT KRT dependence will be defined by the receipt of any form of KRT within +/- 7 days of the 90-day time point following randomization.
Secondary Resource use: cumulative time of continuous KRT Total cumulative duration in hours From randomization to the end of day 5
Secondary Resource use: cumulative time of intermittent KRT Total cumulative duration in hours From randomization to the end of day 5
Secondary Safety: Maximal vasopressor requirements Maximal vasopressor requirements as per the vasoactive-inotropic score recorded during each 24-hour period. From randomization to the end of day 5
Secondary Safety: Severity of illness Total sequential organ failure assessment (SOFA) score recorded during each 24-hour period. From randomization to the end of day 5
Secondary Process measures: Target fluid balance as prescribed in the initial fluid balance prescription for the day From randomization to the end of day 5
Secondary Process measures: Proportion of time in which a neutral fluid balance target is selected by the clinical care team From randomization to the end of day 5
Secondary Process measures: Clinical elements used to assess fluid accumulation From randomization to the end of day 5
Secondary Process measures: The difference between the original target and the fluid balance achieved at the end of each 24-hour period From randomization to the end of day 5
See also
  Status Clinical Trial Phase
Completed NCT04551508 - Delirium Screening 3 Methods Study
Recruiting NCT06037928 - Plasma Sodium and Sodium Administration in the ICU
Completed NCT03671447 - Enhanced Recovery After Intensive Care (ERIC) N/A
Recruiting NCT03941002 - Continuous Evaluation of Diaphragm Function N/A
Recruiting NCT04674657 - Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
Completed NCT04239209 - Effect of Intensivist Communication on Surrogate Prognosis Interpretation N/A
Completed NCT05531305 - Longitudinal Changes in Muscle Mass After Intensive Care N/A
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Completed NCT02916004 - The Use of Nociception Flexion Reflex and Pupillary Dilatation Reflex in ICU Patients. N/A
Recruiting NCT05883137 - High-flow Nasal Oxygenation for Apnoeic Oxygenation During Intubation of the Critically Ill
Completed NCT04479254 - The Impact of IC-Guided Feeding Protocol on Clinical Outcomes in Critically Ill Patients (The IC-Study) N/A
Recruiting NCT04475666 - Replacing Protein Via Enteral Nutrition in Critically Ill Patients N/A
Not yet recruiting NCT04516395 - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae N/A
Not yet recruiting NCT04538469 - Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
Withdrawn NCT04043091 - Coronary Angiography in Critically Ill Patients With Type II Myocardial Infarction N/A
Recruiting NCT02989051 - Fluid Restriction Keeps Children Dry Phase 2/Phase 3
Recruiting NCT02922998 - CD64 and Antibiotics in Human Sepsis N/A
Completed NCT03048487 - Protein Consumption in Critically Ill Patients
Completed NCT02899208 - Can an Actigraph be Used to Predict Physical Function in Intensive Care Patients? N/A
Recruiting NCT02163109 - Oxygen Consumption in Critical Illness